Stock Track | Catalyst Pharmaceuticals Soars 6.78% in Pre-market on Record Q3 Results

Stock Track11-07

Catalyst Pharmaceuticals Inc. (CPRX) witnessed a remarkable pre-market surge of 6.78% on November 7, 2024, driven by the company's outstanding financial performance and positive business updates for the third quarter of 2024.

The biopharmaceutical company reported record total revenues of $128.7 million for Q3 2024, a staggering 25.3% increase compared to the same period last year. This impressive growth was primarily fueled by the robust sales of its flagship product FIRDAPSE, a treatment for Lambert-Eaton myasthenic syndrome (LEMS), which saw net product revenues reaching $79.3 million, up 19.7% year-over-year.

Additionally, the successful launch of AGAMREE, Catalyst's newly introduced treatment for Duchenne muscular dystrophy, exceeded initial expectations, generating net product revenues of $15.0 million in its second full quarter of commercial availability. The company's stellar financial performance and positive business updates surpassed analyst expectations, driving investor optimism and fueling the pre-market stock price surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188111016?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188111016","market":"hk","top_or_hot":-1,"title":"Stock Track | Catalyst Pharmaceuticals Soars 6.78% in Pre-market on Record Q3 Results","media":"Stock Track","content":"<p>Catalyst Pharmaceuticals Inc. (CPRX) witnessed a remarkable pre-market surge of 6.78% on November 7, 2024, driven by the company's outstanding financial performance and positive business updates for the third quarter of 2024.</p>\n\n<p>The biopharmaceutical company reported record total revenues of $128.7 million for Q3 2024, a staggering 25.3% increase compared to the same period last year. This impressive growth was primarily fueled by the robust sales of its flagship product FIRDAPSE, a treatment for Lambert-Eaton myasthenic syndrome (LEMS), which saw net product revenues reaching $79.3 million, up 19.7% year-over-year.</p>\n\n<p>Additionally, the successful launch of AGAMREE, Catalyst's newly introduced treatment for Duchenne muscular dystrophy, exceeded initial expectations, generating net product revenues of $15.0 million in its second full quarter of commercial availability. The company's stellar financial performance and positive business updates surpassed analyst expectations, driving investor optimism and fueling the pre-market stock price surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Catalyst Pharmaceuticals Soars 6.78% in Pre-market on Record Q3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Catalyst Pharmaceuticals Soars 6.78% in Pre-market on Record Q3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 21:03 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalyst Pharmaceuticals Inc. (CPRX) witnessed a remarkable pre-market surge of 6.78% on November 7, 2024, driven by the company's outstanding financial performance and positive business updates for ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPRX","symbol_name":"Catalyst Pharmaceutical Partners","start_time":0,"source_url":"","article_id":"1188111016","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188111016","pubTimestamp":1730984593,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Catalyst Pharmaceuticals Inc.  witnessed a remarkable pre-market surge of 6.78% on November 7, 2024, driven by the company's outstanding financial performance and positive business updates for the third quarter of 2024.The biopharmaceutical company reported record total revenues of $128.7 million for Q3 2024, a staggering 25.3% increase compared to the same period last year. This impressive growth was primarily fueled by the robust sales of its flagship product FIRDAPSE, a treatment for Lambert-","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"股票赛道Catalyst Pharmaceuticals第三季度业绩创历史新高盘前飙升6.78%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1},"content_text":"Catalyst Pharmaceuticals Inc. (CPRX) witnessed a remarkable pre-market surge of 6.78% on November 7, 2024, driven by the company's outstanding financial performance and positive business updates for the third quarter of 2024.\nThe biopharmaceutical company reported record total revenues of $128.7 million for Q3 2024, a staggering 25.3% increase compared to the same period last year. This impressive growth was primarily fueled by the robust sales of its flagship product FIRDAPSE, a treatment for Lambert-Eaton myasthenic syndrome (LEMS), which saw net product revenues reaching $79.3 million, up 19.7% year-over-year.\nAdditionally, the successful launch of AGAMREE, Catalyst's newly introduced treatment for Duchenne muscular dystrophy, exceeded initial expectations, generating net product revenues of $15.0 million in its second full quarter of commercial availability. The company's stellar financial performance and positive business updates surpassed analyst expectations, driving investor optimism and fueling the pre-market stock price surge.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188111016"}